Pharmamarketeer

Astellas Pharma receives US FDA approval to update US product labelling for Xospata

Astellas Pharma Inc. announced that the US Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to update the US product labelling for Xospata (gilteritinib) to include final analysis

Medhc-fases-banner
Advertentie(s)